logo
Cancer Death Rates Down More Than 20 Percent in Last 50 Years but Cases Rising: Report

Cancer Death Rates Down More Than 20 Percent in Last 50 Years but Cases Rising: Report

Epoch Times2 days ago

Cancer death rates have fallen by more than a fifth in the last 50 years but cases are rising, according to a new analysis.
A report from Cancer Research UK found people are now more likely to get cancer than decades ago, but are less likely to die from the disease.
Figures show that the rate of people dying from cancer in the UK has fallen by around 22 percent since the early 1970s, but the rate of people being diagnosed with the disease has risen by almost half.
In 1973, some 328 per 100,000 people died from cancer, dropping to around 252 per 100,000 in 2023, driven by improvements in areas such as diagnosis and better treatment, as well as action to cut smoking.
The study said: 'Survival for all cancers combined in England and Wales has doubled since the early 1970s, but progress has slowed over the last 10 years and remains lower than other comparable countries.
'Survival increased three to five times faster in previous decades, compared with the improvement since 2010.'
Related Stories
5/30/2025
5/24/2025
Cancer Research UK warned that, despite improvement in overall survival, many more people are being diagnosed with cancer compared with 50 years ago.
Incidence rates have risen sharply by almost half (47 percent) across Great Britain over this period, from around 413 cases per 100,000 people to around 607 cases per 100,000 people.
The report listed the preventable causes of cancer, saying smoking remains the biggest cause of cancer, while obesity is linked to 13 different types of the disease.
Other risks include not using sunscreen or failing to cover up in the sun, sunbeds, alcohol, lack of exercise, and diets high in processed meat.
A general view of staff on a NHS hospital ward at Ealing Hospital in London, on Jan. 18, 2023.
Jeff Moore/PA Media
The report pointed out that around half of all new cancer diagnoses are in people aged 70 and over, but incidence rates are currently rising fastest in younger people.
It said: 'In the UK, cancer incidence rates have increased by 23% in people aged 20 to 49 since the early 1990s.
'However, population growth is concentrated in older age groups, so in terms of patient numbers, the biggest increase in cancer cases has been in older people.'
The study also found that, on average, just over half of cancers are diagnosed at an early stage in England (54 percent), and this proportion has not changed for almost a decade.
Michelle Mitchell, Cancer Research UK's chief executive, said: 'It's fantastic to see that thanks to research, cancer death rates have drastically reduced over the last 50 years, and survival has doubled.
'However, there's more that can be done. This report highlights that over 460 people die from cancer every single day in the UK, and too many cases are diagnosed at a late stage.
'If we want to change that, we need bold action from the UK government.
'The upcoming National Cancer Plan for England must improve cancer survival, and transform cancer services.
'If this plan is done right, it could save countless lives across England and ensure people affected by cancer live longer, better lives.'
Cancer Research UK is calling for commitments such as the national rollout of a targeted lung cancer screening programme, quicker access to diagnostic tests for all patients, better access to GPs for speedy diagnosis, and action to improve cancer waiting times.
Its new study is the first ever to include 50 years of cancer death and incidence data for the UK.
Elsewhere, MPs and members of the House of Lords have urged the government to prioritise faster diagnosis of less survivable cancers, which are those that develop in the brain, pancreas, liver, lung, oesophagus, and stomach.
A new report from the All-Party Parliamentary Group (APPG) on Less Survivable Cancers claims these cancers claim 67,000 lives a year, around 42 percent of cancer deaths.
Doubling diagnoses rates in these areas could save an additional 7,500 lives a year, it said.
Paulette Hamilton, chairwoman of the APPG on Less Survivable Cancers, said this is a 'crucial moment for transforming patient outcomes and accelerating survival rates for the less survivable cancers.'
'We're on the brink of research breakthroughs and in the midst of developing potentially game-changing government health reforms,' she added. 'In this backdrop, achieving faster diagnosis for these devastating cancers is finally within reach.'
Professor Peter Johnson, NHS national clinical director for cancer, said: 'The NHS is seeing and treating record numbers of people for cancer, with more people diagnosed at an earlier stage than ever before, and survival rates in England at an all-time high.
'We have developed world-leading programmes, including lung cancer screening in convenient locations such as car parks and using AI to spot skin cancer, making it easier than ever before to get checked.
'The latest data shows that more than three quarters of people received the all-clear or a definitive cancer diagnosis within four weeks of an NHS urgent cancer referral.'

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

ADHD is not really on the rise, study suggests
ADHD is not really on the rise, study suggests

Yahoo

time5 hours ago

  • Yahoo

ADHD is not really on the rise, study suggests

ADHD is not rising despite public perception that cases are increasing, a study suggests. Researchers at King's College London found little evidence to suggest that the prevalence of attention deficit hyperactivity disorder was getting worse, and said many studies suggesting an increase were of too low quality to be trusted. Dr Alex Martin, lecturer in psychology at King's, said: 'The media has been concerned about a 'surge' in ADHD diagnoses for several years. 'While assessments and help-seeking may be increasing, our study has shown significant gaps in the tracking of ADHD prevalence, resulting in a frustratingly unclear picture. 'The best data we have suggests that there has been no meaningful increase in ADHD prevalence, but most of the research is too biased to draw conclusions from.' Anecdotal reports suggest that the UK has had an unprecedented rise in the number of children and adults seeking support for ADHD, with significant backlogs of people currently awaiting assessment. The demand for ADHD diagnoses has exacerbated pressures on the NHS, with a survey by the Pensions Committee in 2023 finding that about one in four people faced delays of two years while one in 10 waited 10 years for an assessment. There were fears that the Covid pandemic and social media may have exacerbated the problem, with many more youngsters experiencing mental health issues during lockdowns. But while calls for assessments are growing, there is little evidence to suggest it was leading to a rise in the overall prevalence of the condition, the study found. The team discovered that studies suggesting ADHD rates were rising were of low quality, using self-reporting surveys, or reported symptoms from parents and teachers, rather than actual clinical diagnoses. Researchers said that the demand for assessments might be driven by increased awareness, rather than more cases. Between January and May last year, there were 25,080 media articles published on ADHD compared with 5,775 articles in the same period in 2014. The growth of the 'neurodiversity movement' may also have played a role in raising the profile of the condition and encouraging more people to seek help. Edmund Sonuga-Barke, professor of developmental psychology at King's, said: 'The neurodiversity movement, with its concentration on personal lived experience and self-compassion as the ultimate reference point for decision-making, is likely driving cultural change. 'In this regard, it's potentially increasing rates of self-referral among adolescents and adults.' In the UK, it's estimated that ADHD affects about 3-5 per cent of children and adults. The US has far higher rates, with nearly 12 per cent of youngsters diagnosed with the condition. This has led to a crackdown by the Trump administration on over-prescribing of ADHD drugs to youngsters. Prof Sonuga-Barke said US and UK rates were likely to be similar and he agreed there should be an investigation. 'I think the prevalence of ADHD is very similar in the US and the UK,' he said. 'I think there's grounds for an investigation to the impact of the prescriptive prescribing rates in the States.' A recent BBC investigation suggested that at least 196,000 adults were on NHS waiting lists for ADHD researchers said that greater awareness of the condition might also mean that young people are now using the term ADHD as 'language of distress', to signal they are struggling, even though they do not have the condition. Prof Phillip Shaw, director of the King's Maudsley Partnership for Children and Young People at King's, said: 'There's both an increased recognition and less stigma around ADHD, which means that people are increasingly coming forward for assessment. 'My hunch is that there's such a huge awareness of ADHD that it's often used as a language of distress. 'It's sometimes used, I suspect, by young people who are expressing that they are struggling, particularly at school, and need help.' This study was funded by NHS England and was conducted by the NIHR Health Protection Research Unit in Emergency Preparedness and Response. Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.

Carlisle Mum gets earlier cancer treatment thanks to 'revolutionary' blood test
Carlisle Mum gets earlier cancer treatment thanks to 'revolutionary' blood test

Yahoo

time7 hours ago

  • Yahoo

Carlisle Mum gets earlier cancer treatment thanks to 'revolutionary' blood test

A mother-of-two from Carlisle says she has been given her life back after receiving targeted cancer treatment. Rebeca Proctor, 41, from Carlisle, was diagnosed with stage 4 non-small-cell lung cancer in January. She was able to begin treatment earlier thanks to a new NHS liquid biopsy blood test, which identified a specific genetic mutation. Ms Proctor said: "When I found out I had stage 4 cancer it felt like I'd been punched in the gut, I was scared – I just thought about my children, and if I would get to see my little girl start nursery, and how I would explain my diagnosis to my children – it was just heart-breaking to think about. "But the medication has given me my life back and my kids have got their mum back. "I'm taking it day by day and for now the treatment is doing what it's meant to be doing and shrinking the tumour, and I've got my energy back. "I know I'm not going to be cured but I've come to terms with my diagnosis and the pills are stopping my cancer cells from spreading – we'll keep fighting this and dealing with what's been thrown at us." The liquid biopsy revealed she had an ALK genetic mutation, allowing her to start a targeted therapy, brigatinib. A traditional tissue biopsy confirmed the result around 10 days later. Ms Proctor is under the care of Dr Sally Hall, a consultant medical oncologist at the Northern Centre for Cancer Care in North Cumbria. The new blood test, now available across the NHS in England, detects fragments of tumour DNA in the bloodstream. It identifies genetic mutations that can guide personalised cancer treatment. NHS England recently announced that up to 15,000 patients with suspected lung cancer could benefit from the test each year. An NHS pilot found that lung cancer patients could start targeted treatment up to 16 days sooner using the liquid biopsy compared to standard tissue biopsies. The pilot also showed that some patients were able to avoid unnecessary chemotherapy and its side effects, improving their quality of life. Professor Peter Johnson, NHS national clinical director for cancer, said: "Liquid biopsies are leading us into a new era of personalised cancer care and it's fantastic that we are now able to expand the use of this revolutionary test on the NHS to help tailor treatment for thousands of patients across the country. "Cutting-edge genomic testing is helping us deliver more targeted and kinder care for patients, enabling some to avoid more intensive treatments such as further chemotherapy, which can have a huge impact." Professor Alastair Greystoke, co-clinical lead of the ctDNA pilot and honorary medical oncologist at Newcastle Hospitals, said: "This is the first ever national implementation of a 'liquid biopsy first' approach to the diagnosis and treatment of a cancer." "Not only has it led to faster and more precise treatment for patients with lung cancer, but we have also been able to show that this is a cost-effective measure for the NHS and set up the framework to evaluate this in other cancers going forward." Professor Dame Sue Hill, chief scientific officer for England, said: "This represents a real step-change in care for eligible lung and breast cancer patients on the NHS. "The liquid biopsy testing enables genomic mutations in the fragments of cancer that enter the bloodstream of these patients to be detected. "This testing is transforming care and helping clinicians match patients earlier, especially when cancer tissue may not be available, with potentially life-extending targeted therapies rapidly and with greater precision."

Pregnant women warned against using weight-loss jabs
Pregnant women warned against using weight-loss jabs

Yahoo

time8 hours ago

  • Yahoo

Pregnant women warned against using weight-loss jabs

Women using weight-loss jabs are being advised to stop if they are trying for a baby, have fallen pregnant or are breastfeeding. Drug safety experts in the UK say it's not known whether taking the medicines, such as Wegovy and Mounjaro, could harm an unborn baby. The advice already appears in patient information leaflets that come with the medicines. But there are concerns that the growing popularity of 'skinny jabs' means many women aren't using the drugs safely or getting the right advice. Natasha Major, 26, started using Mounjaro to lose weight before planning to try for her third baby in a few years' time, but was shocked six weeks later to find she was pregnant. She was taking the contraceptive pill at the time. "I have polycystic ovaries as well, so I can't get pregnant easily or quickly. So it was an even bigger shock that I had, which didn't make any sense to me," she says. She then worried she could be harming the baby or it wouldn't develop properly, so she rang her GP for advice, who told her to stop taking it. "We're over the initial shock now and really happy, just wasn't expected," she says. "The last injection I took, I found out about the pregnancy three hours later and haven't taken it since then. "I've had an early scan to make sure the pregnancy was viable and okay - baby had a little heartbeat and everything looks good," Natasha says. The UK drugs regulator, as well as doctors and pharmacists, are worried that popular GLP-1 medicines, known as Wegovy, Mounjaro, Saxenda, Victoza and Ozempic, are not being used safely. These prescription medicines, which are licensed to treat obesity (and Ozempic for type 2 diabetes), make people feel full by mimicking a hormone released after eating. Mounjaro also acts on another hormone linked to appetite and blood sugar control. They are only available on the NHS to people with a very high BMI, but such is the demand for them that many people are buying them from unregulated sellers on social media or from beauty salons, without any medical advice, as a quick fix to lose weight. How do weight loss drugs like Mounjaro and Wegovy work? Women share their bittersweet experience after taking weight-loss drugs As a precaution, the Medicines and Healthcare products Regulatory Agency (MHRA) says women should use contraception while taking GLP-1 medicines and for a certain period afterwards before trying to become pregnant - two months for Wegovy and Ozempic, and one month for Mounjaro. It also advises that those using Mounjaro and taking an oral contraceptive should also use a condom for four weeks after starting the drug, or switch to another method such as the coil or implant. Weight-loss jabs may make the contraceptive pill less likely to work in those who are overweight or obese, the MHRA says. Women should be told this information when they starting taking the jabs, but there are fears the message is not getting through. Natasha bought Mounjaro online and says she "can't remember reading anything about contraception on there". The MHRA has produced new guidance on weight-loss jabs for people taking them. It's acted now because of a very small number of reports of unintended pregnancies and complications in pregnancy made to its Yellow Card scheme, where the public can report suspected side-effects of medicines. Dr Alison Cave, chief safety officer at the MHRA, said there was evidence from animal studies "that these medicines may harm the unborn baby". "But we don't know whether we have the same effects in humans, so much more data is needed to determine that." Women of child-bearing age are usually not included in clinical trials, which is why there is a lack of safety information for them. "If you are taking this medicine and you are pregnant, you should talk to your doctor about stopping the medicine as soon as possible," she said. Sukhi Basra, vice-chairwoman of the National Pharmacy Association, said women should visit their pharmacist for advice if they are confused about when to stop using the drugs. When it comes to accessing contraception, BPAS, the British Pregnancy Advisory Service, says women in the UK "face significant challenges" when trying to access their method of choice. A lack of appointments, long waiting lists and high costs are just some of the barriers they face, BPAS said, as it called for a better plan for providing the choice women need. 'Skinny jabs' too easy to order online, GP warns Weight-loss drugs tested in head-to-head trial 'WeightWatchers set me up to fail' - Why diet industry is losing to jabs like Ozempic

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store